| Aimee C Morell-watton, MD | |
|
1818 N Meade St, Appleton, WI 54911-3454 | |
| (920) 735-7645 | |
| (920) 735-7618 |
| Full Name | Aimee C Morell-watton |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Experience | 17 Years |
| Location | 1818 N Meade St, Appleton, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073776134 | NPI | - | NPPES |
| 036124972 | Medicaid | IL |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ascension Ne Wisconsin - St Elizabeth Campus | Appleton, WI | Hospital |
| Ascension Calumet Hospital | Chilton, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ascension Medical Group-fox Valley Wisconsin Inc | 0244142420 | 258 |
News Archive
Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).
BioInvent International AB and Human Genome Sciences, Inc. today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies which specifically target antigens discovered by HGS.
Quanterix announced financial results for the three months and twelve months ended Dec. 31, 2018.
A new drug could aid in losing weight and keeping it off. The drug, described in the journal Cell Metabolism on July 26, increases sensitivity to the hormone leptin, a natural appetite suppressant found in the body. Although so far the new drug has only been tested on mice, the findings have implications for the development of new treatments for obesity in humans.
The call came the last week of September, when Neil Mahoney could still stagger from his bed to the porch of his mobile home to let out his boisterous yellow Lab, Ryder.
› Verified 7 days ago
| Entity Name | Ascension Medical Group-fox Valley Wisconsin Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730126392 PECOS PAC ID: 0244142420 Enrollment ID: O20031105000351 |
News Archive
Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).
BioInvent International AB and Human Genome Sciences, Inc. today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies which specifically target antigens discovered by HGS.
Quanterix announced financial results for the three months and twelve months ended Dec. 31, 2018.
A new drug could aid in losing weight and keeping it off. The drug, described in the journal Cell Metabolism on July 26, increases sensitivity to the hormone leptin, a natural appetite suppressant found in the body. Although so far the new drug has only been tested on mice, the findings have implications for the development of new treatments for obesity in humans.
The call came the last week of September, when Neil Mahoney could still stagger from his bed to the porch of his mobile home to let out his boisterous yellow Lab, Ryder.
› Verified 7 days ago
| Entity Name | Ascension Ne Wisconsin, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407803638 PECOS PAC ID: 7719897784 Enrollment ID: O20061027000037 |
News Archive
Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).
BioInvent International AB and Human Genome Sciences, Inc. today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies which specifically target antigens discovered by HGS.
Quanterix announced financial results for the three months and twelve months ended Dec. 31, 2018.
A new drug could aid in losing weight and keeping it off. The drug, described in the journal Cell Metabolism on July 26, increases sensitivity to the hormone leptin, a natural appetite suppressant found in the body. Although so far the new drug has only been tested on mice, the findings have implications for the development of new treatments for obesity in humans.
The call came the last week of September, when Neil Mahoney could still stagger from his bed to the porch of his mobile home to let out his boisterous yellow Lab, Ryder.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Aimee C Morell-watton, MD 122 E College Ave, Appleton, WI 54911-5794 Ph: (920) 996-3264 | Aimee C Morell-watton, MD 1818 N Meade St, Appleton, WI 54911-3454 Ph: (920) 735-7645 |
News Archive
Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).
BioInvent International AB and Human Genome Sciences, Inc. today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies which specifically target antigens discovered by HGS.
Quanterix announced financial results for the three months and twelve months ended Dec. 31, 2018.
A new drug could aid in losing weight and keeping it off. The drug, described in the journal Cell Metabolism on July 26, increases sensitivity to the hormone leptin, a natural appetite suppressant found in the body. Although so far the new drug has only been tested on mice, the findings have implications for the development of new treatments for obesity in humans.
The call came the last week of September, when Neil Mahoney could still stagger from his bed to the porch of his mobile home to let out his boisterous yellow Lab, Ryder.
› Verified 7 days ago
Bessant A Parker, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 1506 S Oneida St, Hospital Service Department, Appleton, WI 54915 Phone: 920-738-2000 | |
Matthew Boese, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1818 N Meade St, Appleton, WI 54911 Phone: 920-735-7645 Fax: 920-735-7618 | |
Dr. Rafal G Ciecierski, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1818 N Meade St, Appleton, WI 54911 Phone: 920-735-7645 Fax: 920-735-7618 | |
Lulseged Zenebe, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1506 S Oneida St, Hospital Service, Appleton, WI 54915 Phone: 920-738-2000 | |
Suranga Mihindu Dharmaratne, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1818 N Meade St, Appleton, WI 54911 Phone: 920-735-7645 Fax: 920-735-7618 | |
Arshad Al-mashhadani, MD Hospitalist Medicare: May Accept Medicare Assignments Practice Location: 1818 N Meade St, Appleton, WI 54911 Phone: 920-735-7645 |